Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
50.04 (USD) • At close September 6, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0.882 | 3.937 | 36.144 | 4.822 | 2.44 | 1.911 | 0.648 | 0 | 0 | 0 |
| Cost of Revenue
| 0.641 | 1.488 | 1.639 | 0.098 | 0.09 | 48.614 | 26.039 | 15.437 | 5.889 | 1.256 | 0 | 0 |
| Gross Profit
| -0.641 | -1.488 | -0.758 | 3.839 | 36.054 | -43.792 | -23.599 | -13.525 | -5.24 | -1.256 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | -0.859 | 0.975 | 0.998 | -9.081 | -9.671 | -7.076 | -8.082 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 31.168 | 16.137 | 36.445 | 98.267 | 89.605 | 48.614 | 26.039 | 15.437 | 5.889 | 1.256 | 0.211 | 0.001 |
| General & Administrative Expenses
| 13.91 | 18.699 | 20.425 | 28.48 | 23.643 | 12.956 | 8.964 | 6.46 | 3.613 | 1.392 | 0.347 | 0 |
| Selling & Marketing Expenses
| -13,896.372 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 13.269 | 18.699 | 20.425 | 28.48 | 23.643 | 12.956 | 8.964 | 6.46 | 3.613 | 1.392 | 0.347 | 0 |
| Other Expenses
| 0 | -0.049 | 11.9 | 13.27 | 4.582 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 44.436 | 34.835 | 56.871 | 126.747 | 113.248 | 61.57 | 35.003 | 21.896 | 9.502 | 2.647 | 0.557 | 0.001 |
| Operating Income
| -45.077 | -39.835 | -55.989 | -122.81 | -77.105 | -56.748 | -32.563 | -19.985 | -8.854 | -2.647 | -0.557 | -0.001 |
| Operating Income Ratio
| 0 | 0 | -63.501 | -31.192 | -2.133 | -11.768 | -13.344 | -10.456 | -13.655 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.474 | -2.511 | 10.349 | 11.541 | 5.651 | 0.093 | -0.042 | -0.014 | 0.002 | 0.129 | -0.001 | -0 |
| Income Before Tax
| -44.603 | -42.347 | -45.64 | -111.269 | -71.454 | -55.672 | -32.422 | -19.999 | -8.851 | -2.54 | -0.602 | -0.001 |
| Income Before Tax Ratio
| 0 | 0 | -51.764 | -28.261 | -1.977 | -11.545 | -13.286 | -10.463 | -13.651 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 13.486 | -0.088 | 0.035 | -2.299 | 1.076 | -0.397 | 0.014 | 0.002 | 0.024 | 0.044 | -0 |
| Net Income
| -44.603 | -55.833 | -45.553 | -111.304 | -69.155 | -55.672 | -32.422 | -19.999 | -8.851 | -2.54 | -0.602 | -0.001 |
| Net Income Ratio
| 0 | 0 | -51.664 | -28.27 | -1.913 | -11.545 | -13.286 | -10.463 | -13.651 | 0 | 0 | 0 |
| EPS
| -10.31 | -13.39 | -11.11 | -42.74 | -32.47 | -29.3 | -19.38 | -14.58 | -8.47 | -3.78 | -0.7 | -3.82 |
| EPS Diluted
| -10.31 | -13.39 | -11.11 | -42.74 | -32.47 | -29.3 | -19.38 | -14.58 | -8.47 | -3.78 | -0.7 | -3.82 |
| EBITDA
| -44.436 | -29.505 | -56.268 | -122.109 | -76.946 | -56.84 | -32.521 | -19.883 | -8.806 | -2.635 | -0.557 | -0 |
| EBITDA Ratio
| 0 | 0 | -63.817 | -31.014 | -2.129 | -11.787 | -13.327 | -10.402 | -13.582 | 0 | 0 | 0 |